Given these key changes during CoM progression, we launched a clinical trial of VEGFR blockade combined with anti-PD1 therapy for distant metastatic CoM patients, which exhibited sufficient tumor-inhibitory efficacy. This evidence concerns the gene PDCD1 and neoplasm.